Medication Use in Severe Anorexia Nervosa: A Danish Register-based Study

Zi-Ping Zhang[1]

Hannah Chatwin[1]

Janne T Larsen [1,2,3]

Loa Clausen [4,5]

Esben Agerbo [1,3]

Trine Munk-Olsen [1,6]

Kathrine Bang Madsen [1,6]

Bjarni J Vilhjálmsson [1,7,8]

Liselotte V Petersen [1,2,3]

Zeynep Yilmaz [1,9,10,11]

1. National Centre for Register-Based Research (NCRR), Aarhus University, Aarhus, Denmark.
2. Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Aarhus University, Aarhus, Denmark.
3. Centre for Integrated Register-Based Research at Aarhus University (CIRRAU), Aarhus University, Aarhus, Denmark.
4. Department of Child and Adolescent Psychiatry, Aarhus University Hospital Psychiatry, Aarhus, Denmark.
5. Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
6. Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
7. Bioinformatics Research Centre, Aarhus University, Denmark.
8. Novo Nodisk Foundation Centre for Genomics Mechanisms of Disease, Broad Institute of MIT and Harvard, Cambridge, MA, United States.
9. Department of Biomedicine, Aarhus University, Aarhus, Denmark.
10. Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
11. Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.

Abstract

Background: Severe anorexia nervosa (AN) represents a subgroup of individuals with AN with prolonged illness duration and poor prognosis. Previous research has reported increased medication use in AN, but prescription patterns in severe AN remain unexplored.

Methods: Utilizing Danish registers, this cohort study included 7,654 individuals diagnosed with AN. We assigned cases to severe AN or less-severe AN groups based on their AN Register-based Severity Index scores. First, we examined trajectories of medication use and compared prescription patterns between groups using logistic regression models. Second, common comorbidity profiles among individuals with severe AN were identified by latent class analysis for further between-group comparisons. Sensitivity analyses were conducted to test alternative definitions of severe AN.

Results: Compared to individuals with less-severe AN, those with severe AN were more likely to be prescribed various medications, including drugs targeting the alimentary tract (OR = 1.44), cardiovascular drugs (OR = 1.12), analgesics (OR = 1.18), and psychotropic drugs (OR = 2.89). Notably, the severe AN group was prescribed medications even in the absence of diagnosed comorbidities and with significantly higher frequencies compared to those with less-severe AN. Within the severe group, five clusters with distinct comorbidity profiles emerged, and we observed an increased use of medication compared to the comorbidity-free cluster.

Conclusion: Our study highlights the higher medication use in individuals with severe AN and the association between medication use and comorbid conditions. These findings underscore the importance of comprehensive and specialized strategies for severe AN.

1. Background

Anorexia nervosa (AN), a serious eating disorder (ED) affecting 4% of females and 0.3% of males worldwide,[1] carries the risk of high chronicity.[2] Follow-up studies have found that 20% of individuals still meet AN criteria five years post-treatment[3-5] , and recovery rates remain below 80% even after 20 years[6-8] , highlighting the critical need for effective treatments.

The treatment of AN is difficult, with limited evidence supporting pharmacological interventions.[9] No medication has been approved by the U.S. Food and Drug Administration for AN[10, 11] or demonstrated consistent or extensive efficacy.[12] Nevertheless, pharmacotherapy is commonly utilized for individuals with AN,[13, 14] often targeting specific symptoms rather than the core pathology. More recently, a Danish population-based study reported higher prescription rates of any type of medication in AN patients compared to population-matched controls.[14] However, existing research rarely distinguishes severe and less-severe AN, leaving pharmacotherapy patterns specific to severe AN poorly understood.

The challenge in treating AN is complicated by the high prevalence of comorbidities. Compared to other mental disorders, AN demonstrates notably higher psychiatric comorbidity rates, ranging from 58% to 87% of individuals with AN having a comorbid psychiatric disorder during their lifetime.[15, 16] Common psychiatric comorbidities include mood disorders,[17, 18] anxiety disorders,[19] obsessive-compulsive disorder,[19, 20] substance use disorders,[21, 22] and personality disorders.[23] Despite their typical association with advanced age, elevated risks of somatic illness,[24] including but not limited to cardiovascular complications,[25, 26] gastrointestinal diseases,[27] osteopenia, and osteoporosis,[28, 29] have been reported in relatively young individuals with AN.

Consequently, treatment objectives typically address both psychopathology and associated medical conditions,[30] leading to considerable variations in medication prescription patterns, particularly across comorbidity profiles and illness severity.

The exploration of pharmacotherapy patterns in severe AN is impeded by the lack of clinical criteria or definition of severity. The recently developed AN Register-based Severity Index (AN-RSI) provides a unique opportunity to distinguish severe cases from the broader AN population in the absence of detailed clinical notes[31] Leveraging data from population registers, AN-RSI is designed to measure AN severity as continuous scores, incorporating multiple register-based indicators that align with key elements of the severity guidelines,[32, 33] ensuring more accurate classification of individuals.

Considering the complexities associated with AN treatment, the aim of this study was to examine medication use in severe AN with two distinct objectives. We first compared medication prescriptions between severe and less-severe AN groups, hypothesizing that severe AN cases would demonstrate significantly higher use of both psychotropic and somatic medications. Additionally, we investigated the association between comorbidity profiles and prescription patterns in severe AN. Specifically, we hypothesized that distinct comorbidity profiles would correlate with varying medication regimens, with certain comorbidity patterns associated with more frequent and diverse medication use.

2. Methods

2.1 Study design

This register-based cohort study comprised all individuals diagnosed with AN (ICD-8: 306.50; ICD-10: F50.0-50.1) in Denmark between 1 January 1991 and 31 December 2011. Cases were identified through the Danish National Patient Register (DNPR) and the Danish Psychiatric Central Research Register (DPCRR).[34, 35] Severity assessment was based on AN-RSI at five years after initial AN diagnosis (see Supplementary Table S1 for

components of the AN-RSI; for complete development details, see Larsen *et al.*[31]). Individuals scoring in the top 20% on AN-RSI were categorized as severe cases, with remaining individuals classified as less-severe. Prescription records between 1996 and 2021 were obtained from the Danish National Prescription Registry,[36] which includes prescriptions redeemed from general practitioners and community pharmacies in Denmark. Unique personal identification numbers from the Danish Civil Registration System facilitated data linkage across nationwide health registers.[37]

To maintain consistency with prescription registries, medications were grouped according to the Anatomical Therapeutic Chemical classification codes.[38] Primary classes of medication included drugs for the alimentary tract (A), cardiovascular drugs (B, C), anti-infective drugs (D, J, P), contraceptives (G), hormonal preparations (H), musculoskeletal drugs (M), analgesics (N02), psychotropic drugs (N, excluding N02), respiratory and sensory drugs (R, S), and others (V). Subclasses of medications of special interest were examined separately. Comorbid diagnoses, including psychiatric and somatic chapters, were coded as either present or absent and captured following the definition listed in Supplementary Table S2.

2.2 Statistical analyses

At the 5-year post-diagnosis point, we classified patients as having severe or less-severe AN based on AN-RSI scores and reported the onset age and sex distributions of both groups. We explored medication use trajectories for these severity groups both retrospectively (from the initial diagnosis to the 5-year classification point) and prospectively (from classification to 10 years post-diagnosis). To quantify differences between two groups, we calculated odds ratios (ORs) with 95% confidence intervals (CIs) for prescriptions during the period spanning from five to ten years post-diagnosis. To delineate the effects of AN severity, we examined medication use patterns over 5–10 years post-diagnosis in patients without psychiatric and somatic comorbidities.

Statistical clustering techniques such as latent class analysis (LCA)[39] were applied to explore the heterogeneity of diseases and comorbidities.[40, 41] We performed LCA to identify common comorbidity profiles in severe AN. Briefly, severe AN cases without any comorbidities were assigned to a separate cluster and excluded from LCA. Models with two to six clusters were assessed, with the optimal model selected based on statistical measures (Supplementary Table S3). Individuals were assigned to clusters according to their highest probability of membership. K-means[42] was employed to validate the robustness of LCA results. ORs for differences in prescription rates across medication classes were compared between groups with and without comorbidities, with p-values adjusted via Benjamini-Hochberg correction.[43] Further comparisons were stratified by comorbidity profile clusters.

Sensitivity analyses examined the association between medication use and AN severity established under two alternative timeframes: 3- and 7-year post-diagnosis. These timeframes were selected to address ongoing discourse in the field regarding optimal illness duration criteria for defining severe AN, ranging from 3 to 7 years or longer, and to validate our findings across different definitions. Prescription patterns were compared between severe and less-severe groups across each timeframe. LCA identified comorbidity profiles among severe AN patients defined by AN-RSI at these alternative timepoints (versus the original 5-year AN-RSI).

3. Results

3.1 Population characteristics

A total of 7654 individuals were included in the main analyses, with 1652 (21.6%) classified as severe AN cases based on AN-RSI. Table 1 outlines the characteristics of the severe

and less-severe AN groups. Individuals with severe AN presented more frequently with comorbid psychiatric disorders and somatic illnesses compared to the less-severe group.

3.2 Severe AN versus less-severe AN

The trajectories of medication use among individuals with severe AN and less-severe AN are shown in Figure 1a, capturing prescriptions over 10 years after first AN diagnosis (5 years before and 5 years after the severity assessment). Medication for somatic illnesses stabilized during follow-up for both groups. However, contraceptives peaked later in the severe AN group, at 8 years after the first AN diagnosis, compared to 5 years in the less-severe AN group. Psychotropic drug prescriptions were consistently higher in severe AN, primarily driven by the difference in antidepressants, psycholeptics, anti-epileptics, and anxiolytics/hypnotics (Figure 1b).

Figure 2 presents the ORs of prescriptions in severe AN compared to less-severe cases 5 years after establishing severity. Individuals with severe AN had higher likelihood of receiving medications for the alimentary tract (OR = 1.4, 95% CI 1.3-1.6), cardiovascular drugs (OR = 1.1, 95% CI 1.0-1.3), analgesics (OR = 1.2, 95% CI 1.1-1.3), and psychotropic drugs (OR = 2.4, 95% CI 2.1-2.7). Conversely, contraceptives and anti-infective drugs were prescribed less frequently to individuals with severe AN, with ORs of 0.7 (95% CI 0.6-0.8) and 0.8 (95% CI 0.6-0.9), respectively.

Among AN cases without comorbidities (10.2% in severe AN; 18.7% in less-severe AN), both groups were prescribed a range of medications (Supplementary Figure S1). The highest prevalence was observed for anti-infective drugs in both groups, with 85.2% in the severe AN group and 87.6% in the less-severe AN group, although the difference was not statistically significant. Compared to less-severe AN cases, severe AN cases received more prescriptions for alimentary tract medications (OR = 1.4, 95% CI 1.0-2.1) and psychotropic drugs (OR = 2.4, 95% CI 1.7–3.3), particularly anti-depressants (OR = 3.4, 95% CI 2.4-4.7)

and psycholeptics (OR = 2.8, 95% CI 1.3–6.2). Medications for somatic conditions—except for vitamins/minerals—showed no significant variation between groups.

3.3 Comorbidity profiles and medications in severe AN

Among the 1652 individuals with severe AN, 1483 (89.8%) had at least one additional diagnosis within the specified study timeframe (Supplementary Table S2), while the remaining 169 patients (10.2%) had no psychiatric or somatic diagnoses. Overall, 71.1% of individuals with severe AN had psychiatric comorbidities, and 74.1% had somatic comorbidities (Table 1).

LCA identified clusters with differing clinical presentation in severe AN (Supplementary Figure S2a). Individuals without comorbidities were assigned to Cluster 1. Cluster 2 (27.8%) comprised AN cases with a low prevalence (< 30%) of both somatic and psychiatric comorbidities. Cluster 3 (42.2%) represented individuals with a medium burden (30–60%) of personality disorders, mood disorders, and anxiety disorders. Cluster 4 (10.2%) was characterized by high proportions (> 60%) of individuals with comorbid personality disorders, anxiety disorders, and self-harm, with moderate prevalence of mood disorders, schizophrenia, and substance use disorders. Individuals assigned to Cluster 5 (9.6%) exhibited high burdens (> 60%) of both psychiatric disorders and somatic illnesses. K-means clustering with 4-item—matching the optimal number of clusters from LCA—generated similar patterns (Supplementary Figure S2b).

Individuals with severe AN were prescribed various medications regardless of comorbidity burden (Table 2). Anti-infective drugs were most commonly prescribed (85.2-96.9% across all clusters). Prescription rate of medications for somatic conditions significantly differed among clusters based on somatic comorbidity burden. Psychotropic drugs were also prescribed frequently, ranging from 47.4% in individuals without comorbidity to over 90% in individuals with a high prevalence of psychiatric disorders (Clusters 4 and 5). Anti-

depressants were the most prevalent psychotropics, ranging from 41.4 % to 88.1%, followed by anxiolytics/hypnotics (10.1–77.4%) and psycholeptics (5.3–80.4%). Compared to those without comorbidities (Cluster 1), AN cases with varying degrees of comorbidity burden (Cluster 2-5) revealed significantly higher odds of receiving all medication classes except contraceptives (Figure 3). Notably, the prescription of psychotropic drugs was 43 times higher in individuals with a high burden of comorbidity (Cluster 5) compared to those without comorbidities. Alimentary tract medication use had approximately two-fold higher odds in low-burden clusters and nearly twenty-fold higher odds in patients with severe somatic disease burden. All pairwise comparisons between clusters (1–4) demonstrated similar trends: clusters with higher comorbidity burden had significantly elevated odds for most medication classes.

3.4 Sensitivity analyses

Using 3-year post-diagnosis severity assessment, the severe AN group showed lower odds than less-severe AN patients of receiving prescribed anti-infective drugs, contraceptives, musculoskeletal drugs, and respiratory and sensory drugs (ORs ranging from 0.62 to 0.84) but higher odds for alimentary tract medications (OR = 1.3, 95% CI 1.2–1.5) (Supplementary Figure S4). The 7-year AN-RSI analysis closely resembled the primary 5-year analysis: severe AN cases had higher likelihood of being prescribed various medications such as drugs for the alimentary tract (OR = 1.6, 95% CI 1.5–1.9), cardiovascular drugs (OR = 1.2, 95% CI 1.1–1.4), analgesics (OR = 1.2, 95% CI 1.1–1.3), and psychotropic drugs (OR = 2.4, 95% CI 2.2–2.7) (Supplementary Figure S5). LCA identified comorbidity clusters across both timeframes (Supplementary Figures S6 and S7). Higher severity scores were associated with a higher burden of comorbidities using 7-year AN-RSI, but not with severity measured over 3 years.

4. Discussion

AN severity is not only a key indicator for clinical outcomes, but also influences pharmacological management strategies. This Danish nationwide study provides the first comprehensive characterization of pharmacotherapy patterns in severe AN. Our findings provide evidence for diverse and increased medication use in individuals with severe AN compared to individuals with less-severe AN, revealing—as per our hypothesis—a comorbidity-driven prescription heterogeneity within severe AN.

In our study, psychotropic medications—predominantly anti-depressants, anti-psychotics, anxiolytics/hypnotics, and anti-epileptics—were the most frequently prescribed for severe AN. Prior research that stratified AN into "early stage" versus "severe and enduring" subtypes reported that 44.3% of AN patients were taking psychotropic medication[44], though between-group differences were not explored. By contrast, an osteoporosis-focused cohort study observed an even higher psychotropic exposure rate (85.6%) in individuals with AN, with similar medication classes predominating.[45] The high prescription rate is consistent with our findings and likely reflects the recruitment of a clinically severe population, mirroring our cohort's characteristics. Furthermore, we identified a higher use of medications targeting somatic complications in severe AN—particularly vitamins, minerals, and bisphosphonates—indicating a high prevalence of osteopenia and osteoporosis in individuals with severe AN,[46, 47] where prolonged restrictive intake and extremely low weight compromise bone health, necessitating further medical management.

The less frequent prescription of contraceptives in individuals with severe AN warrants clinical consideration. Research indicates that patients with AN commonly experience sexual dysfunction including loss of libido, increased sexual anxiety, and avoidance of sexual relationships.[48, 49] This pattern of decreased engagement in romantic relationships or sexual activities may explain the observed decreased contraceptive use in this study. However, contrary to these findings pertaining to reduced sexual activity, it has also been

shown that women with active AN not only have an earlier age of pregnancy than the general population, but also experience higher rates of unplanned pregnancies and subsequent abortions among women with AN compared to those without EDs,[50] which may be a consequence in line by our findings pertaining to lower contraceptive use. Additionally, while contraceptives are sometimes prescribed to address bone density loss or stimulate menstruation in AN,[51, 52] clinicians may hesitate to prescribe them to severe AN patients due to concerns about side effects such as increased depression risk or reduced motivation for weight restoration.[53, 54] Taken together, these findings highlight the importance of addressing contraception needs in individuals with severe AN irrespective of presumed sexual activity and developing clinical guidelines that consider both reproductive health and the unique medical vulnerabilities associated with severe AN.

The diverse prescription patterns we observed in individuals with AN in the absence of comorbidities align with prior literature[14], which reports that among comorbidity-free individuals with AN, over 80% use at least one type of medication, with psychotropic drugs prescribed to more than 25% of this group. Even in the absence of a psychiatric diagnosis, clinicians may prioritize targeting subthreshold psychopathology such as pervasive anxiety, cognitive rigidity, and emotional dysregulation, all of which are frequently observed in AN and associated with poorer treatment outcomes and higher mortality.[55-57] Notably, individuals with severe AN received disproportionally more anti-depressants and anti-psychotics compared to individuals with less-severe AN, reflecting the intense and diverse psychiatric symptom characteristics of severe AN: individuals with severe AN often exhibit sleep disturbances, more frequent obsessive rumination on body image, and anxiety regarding food intake (REF). Furthermore, a higher frequency of medications targeting the alimentary tract in severe AN also provides evidence for clinicians making considerable

efforts to address the latent physiological disturbances and chronic malnutrition, as well as their focus on optimizing the outcomes for their patients with AN.[58]

When accounting for comorbidity patterns, individuals with severe AN with comorbidities had increased use of prescriptions compared to those without comorbidity, indicating how comorbid conditions significantly influence prescriptions as per our hypothesis. Comorbidity profiles significantly influenced medication prescriptions, consistent with our hypothesis. Severe AN patients with comorbidities had increased use of medication compared to those without, paralleling observations in general AN and restrictive ED populations.[14, 59] Furthermore, comparisons across clusters with comorbidity provided robust evidence for the dose-dependent association between comorbidity complexity and prescription frequency.

Sensitivity analyses underscored the stability of our findings and highlighted the importance of timeframe selection in defining AN severity. When 3 years was used to assess the severity, it failed to distinguish severe AN from less-severe AN, likely due to insufficient capturing of overall severity and late-emerging complications during illness progression. In contrast, classifications within 5 and 7 years post-diagnosis yielded consistent results in both prescription patterns and comorbidity profiles, mirroring thresholds commonly used in longitudinal studies of this population.[32, 33] Taken together, our study underscores the benefit of extended timeframes (5–7 years) for severity classifications, which reflect cumulative illness burden better than 3 years and therefore reduce misclassification.

To our knowledge, this is the first study to systematically investigate pharmacotherapy practices in AN with a primary focus on severity. Our work has several additional strengths. First, the use of national health registry data enabled us to capture prescription records across an unselected population of individuals with AN, minimizing selection bias. Second, the longitudinal design with up to 10 years of follow-up allowed us to analyze trends in

prescribing practices over time. Third, stratifying patients into subgroups based on comorbidity profiles provided novel insights into treatment heterogeneity among individuals with AN. Fourth, our analysis incorporated both psychiatric and somatic comorbidities, alongside a history of other EDs, accounting for the possibility that complications emerging later in disease progression may increase medication use, while prior ED diagnoses could further complicate treatment strategies. While this study advances our understanding of medication use in severe AN, key limitations exist. First, differences in medication use between groups may be underestimated since prescriptions during inpatient admissions or specialist care are not captured in the prescription register (linked to CPR). Given higher hospitalization rates in severe AN, this could underreport hospital-related prescriptions. Second, over-the-counter drugs (e.g., nutritional supplements) were not included, underrepresenting adjunctive treatments. Third, lacking clinical parameters limits confounding control; for example, malnutrition or lower body mass index may drive supplement prescriptions, confounding severity-prescription associations. Fourth, the clinical indication for each prescription was unknown, and bidirectional relationships between AN and comorbidities complicated the interpretation. Finally, the generalizability of this study may be limited due to healthcare system variations; validation in other countries is warranted.

In conclusion, by mapping real-world medication use in a national cohort, our study reveals the complex relationship between AN severity, the presence of multiple comorbidities, and pharmacotherapy strategies. We anticipate our findings will bring further clarity to the complexity of managing AN and the necessity of considering distinct clinical presentations, especially in severe AN. We also urge greater clinical and research attention to pharmacotherapy approaches for severe AN in future work.

References

1. van Eeden, A.E., D. van Hoeken, and H.W. Hoek, *Incidence, prevalence and mortality of anorexia nervosa and bulimia nervosa.* Curr Opin Psychiatry, 2021. **34**(6): p. 515-524.
2. Arcelus, J., et al., *Mortality rates in patients with anorexia nervosa and other eating disorders. A meta-analysis of 36 studies.* Arch Gen Psychiatry, 2011. **68**(7): p. 724-31.
3. Ben-Tovim, D.I., et al., *Outcome in patients with eating disorders: a 5-year study.* Lancet, 2001. **357**(9264): p. 1254-7.
4. Steinhausen, H.C., *The outcome of anorexia nervosa in the 20th century.* Am J Psychiatry, 2002. **159**(8): p. 1284-93.
5. Herpertz-Dahlmann, B., et al., *Outcome of childhood anorexia nervosa-The results of a five- to ten-year follow-up study.* Int J Eat Disord, 2018. **51**(4): p. 295-304.
6. Eddy, K.T., et al., *Recovery From Anorexia Nervosa and Bulimia Nervosa at 22-Year Follow-Up.* J Clin Psychiatry, 2017. **78**(2): p. 184-189.
7. Zipfel, S., et al., *Long-term prognosis in anorexia nervosa: lessons from a 21-year follow-up study.* Lancet, 2000. **355**(9205): p. 721-2.
8. Dobrescu, S.R., et al., *Anorexia nervosa: 30-year outcome.* Br J Psychiatry, 2020. **216**(2): p. 97-104.
9. Touyz, S., et al., *Treating severe and enduring anorexia nervosa: a randomized controlled trial.* Psychol Med, 2013. **43**(12): p. 2501-11.
10. Crow, S.J., *Pharmacologic Treatment of Eating Disorders.* Psychiatr Clin North Am, 2019. **42**(2): p. 253-262.
11. Himmerich, H., et al., *Pharmacological treatment of eating disorders, comorbid mental health problems, malnutrition and physical health consequences.* Pharmacol Ther, 2021. **217**: p. 107667.
12. Blanchet, C., et al., *Medication in AN: A Multidisciplinary Overview of Meta-Analyses and Systematic Reviews.* J Clin Med, 2019. **8**(2).
13. Demmler, J.C., et al., *Shining the light on eating disorders, incidence, prognosis and profiling of patients in primary and secondary care: national data linkage study.* Br J Psychiatry, 2020. **216**(2): p. 105-112.
14. Clausen, L., et al., *Pharmacotherapy in anorexia nervosa: A Danish nation-wide register-based study.* J Psychosom Res, 2023. **164**: p. 111077.
15. Hudson, J.I., et al., *The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication.* Biol Psychiatry, 2007. **61**(3): p. 348-58.
16. Udo, T. and C.M. Grilo, *Psychiatric and medical correlates of DSM-5 eating disorders in a nationally representative sample of adults in the United States.* Int J Eat Disord, 2019. **52**(1): p. 42-50.
17. Momen, N.C., et al., *Comorbidity between eating disorders and psychiatric disorders.* International Journal of Eating Disorders, 2022. **55**(4): p. 505-517.
18. Steinhausen, H.C., et al., *Comorbid mental disorders during long-term course in a nationwide cohort of patients with anorexia nervosa.* Int J Eat Disord, 2021. **54**(9): p. 1608-1618.
19. Meier, S.M., et al., *Diagnosed Anxiety Disorders and the Risk of Subsequent Anorexia Nervosa: A Danish Population Register Study.* Eur Eat Disord Rev, 2015. **23**(6): p. 524-30.
20. Yilmaz, Z., et al., *Examination of the shared genetic basis of anorexia nervosa and obsessive-compulsive disorder.* Mol Psychiatry, 2020. **25**(9): p. 2036-2046.

21. Fouladi, F., et al., *Prevalence of Alcohol and Other Substance Use in Patients with Eating Disorders.* Eur Eat Disord Rev, 2015. **23**(6): p. 531-6.
22. Root, T.L., et al., *Substance use disorders in women with anorexia nervosa.* Int J Eat Disord, 2010. **43**(1): p. 14-21.
23. Sansone, R.A., J.L. Levitt, and L.A. Sansone, *The prevalence of personality disorders among those with eating disorders.* Eat Disord, 2005. **13**(1): p. 7-21.
24. Westmoreland, P., M.J. Krantz, and P.S. Mehler, *Medical Complications of Anorexia Nervosa and Bulimia.* Am J Med, 2016. **129**(1): p. 30-7.
25. Giovinazzo, S., et al., *Anorexia nervosa and heart disease: a systematic review.* Eat Weight Disord, 2019. **24**(2): p. 199-207.
26. Tseng, M.M., et al., *Incidence and Risk of Cardiovascular Outcomes in Patients With Anorexia Nervosa.* JAMA Netw Open, 2024. **7**(12): p. e2451094.
27. Santonicola, A., et al., *Eating Disorders and Gastrointestinal Diseases.* Nutrients, 2019. **11**(12).
28. Golden, N.H., *Osteopenia and osteoporosis in anorexia nervosa.* Adolesc Med, 2003. **14**(1): p. 97-108.
29. Grinspoon, S., et al., *Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa.* Ann Intern Med, 2000. **133**(10): p. 790-4.
30. Aigner, M., et al., *World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders.* World J Biol Psychiatry, 2011. **12**(6): p. 400-43.
31. Larsen, J.T., et al., *Construction of a register-based severity index for anorexia nervosa in Denmark: Association with overall and cause-specific mortality.* medRxiv, 2025: p. 2025.02.14.25322233.
32. Broomfield, C., et al., *Labeling and defining severe and enduring anorexia nervosa: A systematic review and critical analysis.* Int J Eat Disord, 2017. **50**(6): p. 611-623.
33. Hay, P. and S. Touyz, *Classification challenges in the field of eating disorders: can severe and enduring anorexia nervosa be better defined?* J Eat Disord, 2018. **6**: p. 41.
34. Lynge, E., J.L. Sandegaard, and M. Rebolj, *The Danish National Patient Register.* Scand J Public Health, 2011. **39**(7 Suppl): p. 30-3.
35. Mors, O., G.P. Perto, and P.B. Mortensen, *The Danish Psychiatric Central Research Register.* Scand J Public Health, 2011. **39**(7 Suppl): p. 54-7.
36. Kildemoes, H.W., H.T. Sorensen, and J. Hallas, *The Danish National Prescription Registry.* Scand J Public Health, 2011. **39**(7 Suppl): p. 38-41.
37. Pedersen, C.B., *The Danish Civil Registration System.* Scand J Public Health, 2011. **39**(7 Suppl): p. 22-5.
38. *WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment,*. 2025; Available from: https://atcddd.fhi.no/atc_ddd_index_and_guidelines/guidelines/.
39. Weller, B.E., N.K. Bowen, and S.J. Faubert, *Latent Class Analysis: A Guide to Best Practice.* Journal of Black Psychology, 2020. **46**(4): p. 287-311.
40. Duncan, A.E., et al., *Are there subgroups of bulimia nervosa based on comorbid psychiatric disorders?* Int J Eat Disord, 2005. **37**(1): p. 19-25.
41. Steiger, H., et al., *Trait-defined eating-disorder subtypes and history of childhood abuse.* Int J Eat Disord, 2010. **43**(5): p. 428-32.
42. Hartigan, J.A. and M.A. Wong, *Algorithm AS 136: A K-Means Clustering Algorithm.* Journal of the Royal Statistical Society. Series C (Applied Statistics), 1979. **28**(1): p. 100-108.

43. Benjamini, Y. and Y. Hochberg, *Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing.* Journal of the Royal Statistical Society: Series B (Methodological), 2018. **57**(1): p. 289-300.
44. Ambwani, S., et al., *A multicenter audit of outpatient care for adult anorexia nervosa: Symptom trajectory, service use, and evidence in support of "early stage" versus "severe and enduring" classification.* Int J Eat Disord, 2020. **53**(8): p. 1337-1348.
45. Garner, D.M., et al., *Psychotropic medications in adult and adolescent eating disorders: clinical practice versus evidence-based recommendations.* Eat Weight Disord, 2016. **21**(3): p. 395-402.
46. Steinman, J. and A. Shibli-Rahhal, *Anorexia Nervosa and Osteoporosis: Pathophysiology and Treatment.* J Bone Metab, 2019. **26**(3): p. 133-143.
47. Diaz-Marsa, M., I. Alberdi-Paramo, and L. Niell-Galmes, *Nutritional supplements in eating disorders.* Actas Esp Psiquiatr, 2017. **45**(Supplement): p. 26-36.
48. Pinheiro, A.P., et al., *Sexual functioning in women with eating disorders.* Int J Eat Disord, 2010. **43**(2): p. 123-9.
49. Price, T., et al., *Sexual function and dysfunction among women with anorexia nervosa: A systematic scoping review.* Int J Eat Disord, 2020. **53**(9): p. 1377-1399.
50. Bulik, C.M., et al., *Unplanned pregnancy in women with anorexia nervosa.* Obstet Gynecol, 2010. **116**(5): p. 1136-40.
51. Maimoun, L., et al., *Oral contraceptives partially protect from bone loss in young women with anorexia nervosa.* Fertil Steril, 2019. **111**(5): p. 1020-1029 e2.
52. Golden, N.H., et al., *Resumption of menses in anorexia nervosa.* Arch Pediatr Adolesc Med, 1997. **151**(1): p. 16-21.
53. Skovlund, C.W., et al., *Association of Hormonal Contraception With Depression.* JAMA Psychiatry, 2016. **73**(11): p. 1154-1162.
54. Bergstrom, I., et al., *Women with anorexia nervosa should not be treated with estrogen or birth control pills in a bone-sparing effect.* Acta Obstet Gynecol Scand, 2013. **92**(8): p. 877-80.
55. Fewell, L.K., C.A. Levinson, and L. Stark, *Depression, worry, and psychosocial functioning predict eating disorder treatment outcomes in a residential and partial hospitalization setting.* Eat Weight Disord, 2017. **22**(2): p. 291-301.
56. Edakubo, S. and K. Fushimi, *Mortality and risk assessment for anorexia nervosa in acute-care hospitals: a nationwide administrative database analysis.* BMC Psychiatry, 2020. **20**(1): p. 19.
57. Kask, J., et al., *Mortality in Women With Anorexia Nervosa: The Role of Comorbid Psychiatric Disorders.* Psychosom Med, 2016. **78**(8): p. 910-919.
58. Himmerich, H. and J. Treasure, *Psychopharmacological advances in eating disorders.* Expert Rev Clin Pharmacol, 2018. **11**(1): p. 95-108.
59. Monge, M.C., et al., *Use of Psychopharmacologic Medications in Adolescents With Restrictive Eating Disorders: Analysis of Data From the National Eating Disorder Quality Improvement Collaborative.* J Adolesc Health, 2015. **57**(1): p. 66-72.

Table 1.

Characteristics of patients with severe and non-severe anorexia nervosa

Characteristics	Severe AN (%)[1]	Less-severe AN (%)[1]	P-value[2]
N	1652 (21.6)	6002 (78.4)	
Sex			0.004
Female	1572 (95.2)	5592 (93.2)	
Male	80 (4.8)	410 (6.8)	
Age at AN diagnosis (years)	19.6 (6.7)	19.7 (6.2)	<0.001
Standardized AN severity score	1.40 (1.4)	-0.39 (0.3)	<0.001
Had any comorbidity	1483 (89.8)	4880 (81.3)	<0.001
Had any psychiatric comorbidity	1175 (71.1)	3219 (53.6)	0.700
Organic disorders	35 (2.1)	66 (1.1)	<0.001
Substance use disorders	199 (12.1)	529 (9.7)	<0.001
Schizophrenia	231 (14.0)	408 (6.8)	0.082
Mood disorders	594 (36.0)	1399 (23.3)	0.003
Anxiety disorders	641 (38.8)	1667 (27.8)	<0.001
Sleep disorders	9 (0.5)	18 (0.3)	0.137
Personality disorders	575 (34.8)	1350 (22.5)	<0.001
Intellectual disorders	38 (2.3)	89 (1.5)	<0.001
Developmental disorders	87 (5.3)	173 (2.9)	<0.001
Behavioral disorders	231 (14.0)	549 (9.1)	<0.001
Habit impulse	10 (0.6)	10 (0.2)	0.002
Had any somatic comorbidity	1224 (74.1)	3989 (66.5)	<0.001
Infectious	224 (13.6)	697 (11.6)	<0.001
Endocrine	176 (10.7)	400 (6.7)	<0.001
Injuries	604 (36.6)	2132 (35.5)	<0.001
Neurological	115 (7.0)	354 (5.9)	0.300
Circulatory	135 (8.2)	273 (4.5)	<0.001
Respiratory	281 (17.0)	951 (15.8)	0.014
Gastrointestinal	158 (9.6)	460 (7.7)	<0.001
Skin	201 (12.2)	445 (7.4)	<0.001
Musculoskeletal	302 (18.3)	1223 (20.4)	0.400
Genitourinary	50 (3.0)	158 (2.6)	0.400
Congenital	104 (6.3)	310 (5.2)	0.700
Self-harm	451 (27.3)	933 (15.5)	<0.001
Any medication	1,504 (99)	5,958 (98)	0.017
Total number of medications	4.2 (1.7)	3.8 (1.7)	<0.001

AN: anorexia nervosa

[1]n (%); Mean (SD); Median (25th-75th percentile)

[2]Pearson's Chi-squared test; Wilcoxon rank sum test; Fisher's exact test

Figure 1a.

Trajectory of medication prescriptions in severe vs less-severe anorexia nervosa within 10 years post-diagnosis



Note. The red dashed line indicates the year of severity assessment. The percentage of patients with prescriptions was calculated as the proportion who redeemed at least twice prescriptions within discrete one-year intervals following their first AN diagnosis.

Figure 1b.

Trajectory of psychotropic prescriptions in severe vs less-severe anorexia nervosa within 10 years post-diagnosis



Note. Other NS drugs: other nervous system drugs
Red dashed line indicates year of severity assessment.

Figure 2.

Medication prescriptions in patients with severe vs less-severe anorexia nervosa between 5 and 10 years post-diagnosis

Medication	Severe AN (%)	Less-severe AN (%)	Odds Ratio (95% CI)	P-value
Alimentary tract	46.3	37.5	1.44 (1.29, 1.60)	< 0.001
Gastrointestinal	38.7	32.2	1.33 (1.19, 1.49)	< 0.001
Vitamins/Minerals	14.0	4.2	3.76 (3.12, 4.54)	< 0.001
Cardiovascular drugs	25.8	23.8	1.12 (0.98, 1.26)	0.047
Iron preparations	2.7	1.8	1.56 (1.09, 2.22)	0.009
Anti–infective drugs	91.2	93.2	0.75 (0.62, 0.92)	0.003
Contraceptives	69.7	76.9	0.69 (0.61, 0.78)	< 0.001
Hormonal preparation drugs	9.9	9.0	1.12 (0.93, 1.34)	0.129
Thyroid therapy	3.4	2.9	1.16 (0.86, 1.58)	0.19
Musculoskeletal drugs	39.7	42.0	0.91 (0.81, 1.01)	0.044
NSAID	38.8	41.2	0.90 (0.81, 1.01)	0.04
Bisphosphonates	1.3	0.6	2.30 (1.35, 3.93)	0.001
Immunomodulating drugs	1.5	1.9	0.78 (0.50, 1.21)	0.154
Analgesics	35.1	31.5	1.18 (1.05, 1.32)	0.003
Psychotropic drugs	77.1	58.5	2.39 (2.11, 2.71)	< 0.001
Anti–epileptics	15.6	10.3	1.62 (1.38, 1.89)	< 0.001
Psycholeptics	36.1	16.2	2.92 (2.59, 3.30)	< 0.001
Anxiolytics/Hypnotics	38.3	25.2	1.84 (1.64, 2.06)	< 0.001
Anti–depressants	65.4	42.6	2.55 (2.28, 2.86)	< 0.001
Psychostimulants	4.2	4.2	1.00 (0.76, 1.32)	0.5
Other NS drugs	10.8	7.1	1.60 (1.33, 1.92)	< 0.001
Respiratory and sensory drugs	57.8	61.0	0.87 (0.78, 0.98)	0.01
Other	0.4	0.6	0.67 (0.30, 1.50)	0.211



Note. AN: anorexia nervosa
CI: confidence interval
NSAID: nonsteroidal anti-inflammatory drugs
Other NS drugs: other nervous system drugs

Table 2.

Medication prescriptions by comorbidity profiles in patients with severe anorexia nervosa

Characteristics	**Without comorbidity**	**Low burden of comorbidity**	**Medium burden of personality disorders, mood and anxiety disorders**	**High burden of psychiatric disorders and self-harm condition**	**High burden of comorbidity**
N	169	459	697	168	159
Age at AN diagnosis (years)	19.6 (6.2)	19.6 (6.7)	20.1 (6.7)	19.9 (6.4)	19.9 (6.9)
Medication (%)					
Alimentary tract	25.4	41.4	40.8	65.5	86.8
Gastrointestinal	20.7	33.1	32.6	58.9	79.9
Vitamins/Minerals	5.9	11.1	12.9	20.2	29.6
Cardiovascular drugs	11.8	24.8	23.3	29.8	50.3
Anti-infective drugs	85.2	92.8	90.0	92.9	96.9
Contraceptives	65.1	71.9	68.9	67.3	74.2
Hormonal preparation drugs	3.0	11.6	8.0	6.0	25.2
Musculoskeletal drugs	19.5	38.3	36.0	51.2	68.6
Analgesics	13.0	35.1	29.0	45.2	74.8
Psychotropic drugs	47.3	65.8	83.2	93.5	97.5
Anti-depressants	41.4	47.1	72.9	88.1	87.4
Anxiolytics/Hypnotics	10.1	22.7	38.5	71.4	77.4
Psycholeptics	5.3	12.8	38.5	80.4	78.6
Respiratory and sensory drugs	40.8	60.4	53.2	62.5	83.7

Note: Age presented as mean (standard deviation) in years; medication use measured during the 5-year period following severity classification and presented as percentages (%)

Figure 3.

Medication prescriptions in severe anorexia nervosa patients with distinct comorbidity profiles

Medication	Odds Ratio (95% CI)	P-value
	Reference: Severe AN Patients without comorbidity	
Alimentary tract		
Cluster 2	2.07 (1.40, 3.07)	<0.001
Cluster 3	2.02 (1.38, 2.94)	<0.001
Cluster 4	5.56 (3.47, 8.89)	<0.001
Cluster 5	19.26 (10.84, 34.22)	<0.001
Anti–infective drugs		
Cluster 2	2.24 (1.29, 3.90)	0.003
Cluster 3	1.56 (0.95, 2.54)	0.051
Cluster 4	2.26 (1.09, 4.66)	0.019
Cluster 5	5.35 (1.99, 14.34)	<0.001
Cardiovascular drugs		
Cluster 2	2.46 (1.47, 4.11)	<0.001
Cluster 3	2.26 (1.37, 3.71)	<0.001
Cluster 4	3.16 (1.78, 5.59)	<0.001
Cluster 5	7.54 (4.31, 13.22)	<0.001
Contraceptives		
Cluster 2	1.37 (0.94, 2.00)	0.06
Cluster 3	1.19 (0.83, 1.69)	0.197
Cluster 4	1.1 (0.70, 1.73)	0.38
Cluster 5	1.54 (0.96, 2.48)	0.047
Hormonal preparation drugs		
Cluster 2	4.28 (1.68, 10.9)	<0.001
Cluster 3	2.87 (1.13, 7.27)	0.016
Cluster 4	2.08 (0.69, 6.21)	0.143
Cluster 5	11.03 (4.22, 28.77)	<0.001
Musculoskeletal drugs		
Cluster 2	2.56 (1.68, 3.92)	<0.001
Cluster 3	2.32 (1.54, 3.50)	<0.001
Cluster 4	4.32 (2.66, 7.03)	<0.001
Cluster 5	8.98 (5.41, 14.91)	<0.001
Analgesics		
Cluster 2	3.61 (2.22, 5.88)	<0.001
Cluster 3	2.73 (1.69, 4.39)	<0.001
Cluster 4	5.52 (3.21, 9.48)	<0.001
Cluster 5	19.88 (11.2, 35.28)	<0.001
Psychotropic drugs		
Cluster 2	2.14 (1.5, 3.06)	<0.001
Cluster 3	5.52 (3.84, 7.92)	<0.001
Cluster 4	15.88 (8.03, 31.4)	<0.001
Cluster 5	43.11 (15.28, 121.66)	<0.001
Respiratory and sensory drugs		
Cluster 2	2.21 (1.54, 3.16)	<0.001
Cluster 3	1.65 (1.17, 2.32)	0.003
Cluster 4	2.42 (1.56, 3.74)	<0.001
Cluster 5	7.41 (4.41, 12.47)	<0.001



Note. CI: confidence interval
Cluster 1: without any comorbidities
Cluster 2: with low burden of comorbidities
Cluster 3: with medium burden of personality, mood and self-harm conditions
Cluster 4: with high burden of personality disorders and self-harm conditions
Cluster 5: with high burden of comorbidities

Supplementary Table S1.

Anorexia Nervosa Register-based Severity Index

Variable	Definition	Weight
Early onset	First AN-related hospital contact (inpatient or outpatient) before age 10	1 point.
Late onset	First AN-related hospital contact (inpatient or outpatient) after age 25	1 point.
Inpatient admissions	Count of recorded inpatient hospital admissions with AN diagnosis.	2 points per admission.
Outpatient contacts	Number of outpatient treatment contacts with AN diagnosis, excluding initial treatment series.	1 point per contact.
Treatment length	Length of aggregate period of inpatient and outpatient treatment. For inpatient admission: calculated as interval between admission and discharge dates. For outpatient episodes: calculated as 0.5 × (interval between start and end date) + 0.5 × total treatment days	1 point per complete year.
Illness duration	Time from initial AN diagnosis to most recent treatment day within the 5-year follow-up period (primary definition) or until each specific treatment timepoint (continuously updated definition used in sensitivity analyses).	1 point per complete year.

Note. AN: anorexia nervosa

Supplementary Table S2a.

Definition of psychiatric comorbidity

Comorbidity	International Classification of Disease (ICD) codes		Definition
	ICD-10	ICD-8	
Psychiatric disorders: DSM-IV Axis I			
Substance Use	F10-F19	291.x9, 294.39, 303.x9, 303.20, 303.28, 303.90, 304.x9	Having diagnosis during the period from first AN diagnosis to 10 years afterwards.
Mood	F30-F39	296.x9 (excluding 296.89), 298.09, 298.19, 300.49, 301.19	
Neurotic	F40-F48	300.x9 (excluding 300.49), 305.x9, 305.68, 307.99	
Other psychiatric disorders			
Organic	F00-F09	290.09, 290.10, 290.11, 290.18, 290.19, 292.x9, 293.x9, 294.x9, 309.x9	Having diagnosis during the period from age 6 to 10 years after first AN diagnosis.
Schizophrenia	F20-F29	295.x9, 296.89, 297.x9, 298.29-298.99, 299.04, 299.05, 299.09, 301.83	
Sleep	F51	306.49	
Personality	F60-F62	301.x9, 301.80-301.84	
Habit impulse	F63		
Intellctual	F70-F79	311-315	
Developmental	F84	299.00, 299.01, 299.02, 299.03	
Behavioral and emotional	F90-F98	306·x9, 308·0x	

Note. **Rationale for Psychiatric Comorbidity Assessment:**
The distinction between DSM-IV Axis I disorders and other psychiatric disorders acknowledges the differential impact these conditions may have on AN treatment approaches. Mood, anxiety, and substance use disorders frequently co-occur with AN and may directly influence both disease progression and medication selection. The longitudinal timeframe (from first AN diagnosis until ten years thereafter) for Axis I disorders appropriately captures comorbidities that may develop in response to or concurrent with AN. The extended timeframe for other psychiatric disorders (from age six) acknowledges the developmental origins of conditions like personality disorders and intellectual/developmental disorders, which may predate the AN diagnosis but still influence treatment decisions.

Supplementary Table S2b.

Definition somatic comorbidity

Comorbidity	International Classification of Disease (ICD) codes ICD-10	ICD-8	Definition
Somatic diseases			
Respiratory	J00-J46, R05-R06	460-466, 470-486, 490-493, 502-508, 783	Having diagnosis during the period from age 6 to 10 years after first AN diagnosis.
Infection	A00-B99	000-136	
Musculoskeletal	M00-M68	710-718	
Gastronintestinal	K25-K37,K70-K85	530-535, 540-542, 563, 570-577	
Endorine	E00-E35	240-246,250-259	
Skin	L00-L54, L90-L95	680-690,701,708-709	
Neurological	G00-G47, G60-G73, G91	320-358	
Circulatory	I00-I79, I98.3	390-448, 450	
Cogenital malformations	Q00-Q99	740-759	
Genitourinary	N00-N08, N10-N12, N20-N21, N41, N45	580-584, 590, 592, 594, 601, 604	
Immune	D80-D89		
Injuries	S00-T35, T66-T98, V01-V99, X85-Y98	N800-N999, E807-E949, E960-E999	
Self-harm	T36-T65, S50, S51, S55, S59, S60, S61, S65, S69,X60-X84	E950-959	

Note. **Rationale for Somatic Comorbidity Assessment:**
Recording somatic conditions from age six captures pre-existing medical conditions that may complicate AN treatment or influence medication selection. The extended follow-up (until ten years post-diagnosis) allows for identification of emerging somatic complications of AN itself, which might necessitate additional pharmacological interventions. This comprehensive timeframe acknowledges that somatic comorbidities may be both contributors to and consequences of severe AN, both of which could influence medication prescribing patterns.

Supplementary Table S3.

Model fit statistics for latent class analysis

N	AIC	BIC	Maximum Likelihood	Entropy	Sample Proportion
2	24706.7	24966.5	-12304.4	8.3057	0.23/0.77
3	24587.7	24980.0	-12219.8	8.2645	0.33/0.21/0.46
4	24526.6	25071.5	-12174.3	8.2173	0.47/0.11/0.31/0.11
5	24542.3	25199.7	-12147.1	8.1913	0.03/0.05/0.04/0.19/0.7

Note. AIC = Akaike information criterion; BIC = Bayesian Information Criterion. The 4-class solution was selected based on optimal balance between statistical fit indices, clinical interpretability, and to ensure each cluster contained more than 10% of the total sample.

Supplementary Figure S1.

Medication prescriptions in severe vs less-severe anorexia nervosa patients without comorbidities

Medication	Severe AN (%)	Less-severe AN (%)	Odds Ratio (95% CI)	P-value
Alimentary tract	25.4	19.5	1.41 (0.97, 2.05)	0.046
Gastrointestinal	20.7	15.7	1.40 (0.94, 2.11)	0.062
Vitamins/Minerals	5.9	2.2	2.76 (1.3, 5.85)	0.006
Cardiovascular drugs	11.8	13.5	0.86 (0.52, 1.42)	0.323
Anti–infective drugs	85.2	87.6	0.81 (0.51, 1.29)	0.226
Contraceptives	65.1	76.0	0.59 (0.42, 0.83)	0.001
Hormonal preparation drugs	3.0	3.9	0.75 (0.29, 1.91)	0.346
Musculoskeletal drugs	19.5	22.8	0.82 (0.55, 1.23)	0.195
NSAID	19.5	22.6	0.83 (0.55, 1.24)	0.21
Analgesics	13.0	11.1	1.20 (0.74, 1.96)	0.267
Psychotropic drugs	47.3	27.3	2.40 (1.72, 3.33)	<0.001
Psycholeptics	5.3	2.0	2.81 (1.27, 6.22)	0.008
Anxiolytics/Hypnotics	10.1	7.6	1.36 (0.79, 2.36)	0.168
Anti–depressants	41.4	17.4	3.36 (2.39, 4.74)	<0.001
Respiratory and sensory drugs	40.8	47.1	0.78 (0.56, 1.08)	0.076



Note. AN: anorexia nervosa
CI: confidence interval
NSAID: nonsteroidal anti-inflammatory drugs

Supplementary Figure S2a.

Comorbidity profiles of patients with severe anorexia nervosa (derived from latent class analysis)

Cluster 1: Severe AN patients without any comorbidities
N = 169, AN-RSI = 1.18 (1.17)[1]

Cluster 2: Severe AN patients with low burden of comorbidities
N = 459, AN-RSI = 1.27 (1.40)[1]



Cluster 3: Severe AN patients with medium burden of personality, mood, and anxiety disorders
N = 697, AN-RSI = 1.36 (1.17)[1]



Cluster 4: Severe AN patients with high burden of personality disorders, and self-harm conditions
N = 168, AN-RSI = 1.83 (1.46)[1]



Cluster 5: Severe AN patients with high burden comorbidities
N = 159, AN-RSI = 1.94 (1.49)[1]



Note. AN-RSI: Anorexia Nervosa Register-based Severity Index
[1]Mean(standard deviation);
Comorbidities with less than five cases were set to zero.

Supplementary Figure S2b.

Comorbidity profiles of patients with severe anorexia nervosa (derived from k-means)

Cluster 1: Severe AN patients without any comorbidities
N = 169, AN-RSI = 1.18 (1.17)[1]

Cluster 2: Severe AN patients with low burden of comorbidities
N = 619, AN-RSI = 1.22 (1.30)[1]



Cluster 3: Severe AN patients with medium burden of personality, mood, and anxiety disorders
N = 341, AN-RSI = 1.36 (1.27)[1]



Cluster 4: Severe AN patients with high burden of personality disorders, and self-harm conditions
N = 369, AN-RSI = 1.64 (1.42)[1]



Cluster 5: Severe AN patients with high burden comorbidities
N = 154, AN-RSI = 1.81 (1.31)[1]



Note. AN-RSI: Anorexia Nervosa Register-based Severity Index
[1]Mean(standard deviation);
Comorbidities with less than five cases were set to zero.

Supplementary Figure S3.

Medication prescriptions in severe anorexia nervosa patients with distinct comorbidity profiles

Medication	Odds Ratio (95% CI)	P-value
Cluster 5 vs 2		
Alimentary tract	9.30 (5.67, 15.27)	<0.001
Anti–infective drugs	2.39 (0.92, 6.22)	0.051
Cardiovascular drugs	3.06 (2.10, 4.46)	<0.001
Contraceptives	1.13 (0.75, 1.69)	0.322
Hormonal preparation drugs	2.57 (1.63, 4.07)	<0.001
Immunomodulating drugs	1.60 (0.58, 4.39)	0.263
Musculoskeletal drugs	3.51 (2.39, 5.15)	<0.001
Analgesics	5.51 (3.67, 8.27)	<0.001
Psychotropic drugs	20.14 (7.33, 55.37)	<0.001
Anti–depressants	7.82 (4.73, 12.93)	<0.001
Anti–epileptics	23.97 (13.89, 41.37)	<0.001
Anxiolytics/Hypnotics	11.66 (7.58, 17.95)	<0.001
Psycholeptics	24.93 (15.62, 39.78)	<0.001
Psychostimulants	15.83 (4.52, 55.47)	<0.001
Other NS drugs	15.45 (8.25, 28.91)	<0.001
Respiratory and sensory drugs	3.36 (2.12, 5.32)	<0.001
Other	5.83 (0.53, 64.78)	0.168
Cluster 4 vs 2		
Alimentary tract	5.52 (0.50, 61.25)	0.182
Anti–infective drugs	1.10 (0.76, 1.58)	0.346
Cardiovascular drugs	7.42 (3.91, 14.09)	<0.001
Contraceptives	1.53 (1.07, 2.19)	0.013
Hormonal preparation drugs	0.49 (0.11, 2.24)	0.267
Immunomodulating drugs	1.69 (1.18, 2.41)	0.003
Musculoskeletal drugs	0.48 (0.24, 0.98)	0.028
Analgesics	0.80 (0.55, 1.18)	0.152
Psychotropic drugs	1.01 (0.51, 2.00)	0.5
Anti–depressants	1.28 (0.87, 1.90)	0.127
Anti–epileptics	2.69 (1.86, 3.88)	<0.001
Anxiolytics/Hypnotics	14.25 (7.63, 26.61)	<0.001
Psycholeptics	27.74 (17.36, 44.31)	<0.001
Psychostimulants	20.54 (6.02, 70.10)	<0.001
Other NS drugs	8.53 (5.72, 12.73)	<0.001
Respiratory and sensory drugs	11.57 (6.68, 20.05)	<0.001
Other	8.32 (5.04, 13.75)	<0.001
Cluster 3 vs 2		
Alimentary tract	0.97 (0.77, 1.24)	0.437
Anti–infective drugs	0.69 (0.45, 1.07)	0.059
Cardiovascular drugs	0.92 (0.70, 1.21)	0.291
Contraceptives	0.86 (0.67, 1.12)	0.15
Hormonal preparation drugs	0.67 (0.45, 0.99)	0.029
Immunomodulating drugs	0.29 (0.10, 0.85)	0.016
Musculoskeletal drugs	0.90 (0.71, 1.15)	0.229
Analgesics	0.76 (0.59, 0.97)	0.017
Psychotropic drugs	2.58 (1.95, 3.40)	<0.001
Anti–depressants	3.02 (2.36, 3.87)	<0.001
Anti–epileptics	3.51 (2.13, 5.76)	<0.001
Anxiolytics/Hypnotics	2.13 (1.63, 2.78)	<0.001
Psycholeptics	4.24 (3.10, 5.79)	<0.001
Psychostimulants	6.84 (2.07, 22.53)	<0.001
Other NS drugs	2.94 (1.62, 5.33)	<0.001
Respiratory and sensory drugs	0.75 (0.59, 0.95)	0.01
Other	0.66 (0.04, 10.55)	0.5



Note. CI: confidence interval
NSAID: nonsteroidal anti-inflammatory drugs
Other NS drugs: other nervous system drugs

Supplementary Figure S3. (continued)

Medication prescriptions in severe anorexia nervosa patients with distinct comorbidity profiles

Medication	Odds Ratio (95% CI)	P-value
Cluster 5 vs 3		
Alimentary tract	9.56 (5.89, 15.49)	<0.001
Anti–infective drugs	3.44 (1.36, 8.67)	0.004
Cardiovascular drugs	3.34 (2.34, 4.78)	<0.001
Contraceptives	1.30 (0.88, 1.92)	0.109
Hormonal preparation drugs	3.85 (2.45, 6.04)	<0.001
Immunomodulating drugs	5.43 (1.64, 18.01)	0.004
Musculoskeletal drugs	3.87 (2.68, 5.60)	<0.001
Analgesics	7.29 (4.92, 10.81)	<0.001
Psychotropic drugs	7.82 (2.84, 21.51)	<0.001
Anti–depressants	2.59 (1.57, 4.25)	<0.001
Anti–epileptics	6.84 (4.68, 9.98)	<0.001
Anxiolytics/Hypnotics	5.47 (3.66, 8.17)	<0.001
Psycholeptics	5.89 (3.91, 8.86)	<0.001
Psychostimulants	2.32 (1.21, 4.42)	0.008
Other NS drugs	5.26 (3.43, 8.04)	<0.001
Respiratory and sensory drugs	4.49 (2.88, 7.02)	<0.001
Cluster 4 vs 3		
Alimentary tract	2.76 (1.94, 3.92)	<0.001
Anti–infective drugs	1.45 (0.77, 2.74)	0.157
Cardiovascular drugs	1.40 (0.96, 2.04)	0.048
Contraceptives	0.93 (0.65, 1.33)	0.378
Hormonal preparation drugs	0.72 (0.36, 1.45)	0.226
Immunomodulating drugs	1.67 (0.32, 8.67)	0.446
Musculoskeletal drugs	1.86 (1.33, 2.62)	<0.001
Analgesics	2.02 (1.43, 2.86)	<0.001
Psychotropic drugs	2.88 (1.51, 5.48)	<0.001
Anti–depressants	2.75 (1.68, 4.52)	<0.001
Anti–epileptics	3.30 (2.25, 4.85)	<0.001
Anxiolytics/Hypnotics	4.00 (2.77, 5.78)	<0.001
Psycholeptics	6.55 (4.35, 9.87)	<0.001
Psychostimulants	3.00 (1.66, 5.44)	<0.001
Other NS drugs	4.85 (3.18, 7.39)	<0.001
Respiratory and sensory drugs	1.46 (1.04, 2.07)	0.019
Other	8.39 (0.76, 93.03)	0.09
Cluster 5 vs 4		
Alimentary tract	3.46 (1.98, 6.06)	<0.001
Anti–infective drugs	2.37 (0.82, 6.88)	0.084
Cardiovascular drugs	2.39 (1.52, 3.76)	<0.001
Contraceptives	1.40 (0.87, 2.26)	0.104
Hormonal preparation drugs	5.31 (2.55, 11.05)	<0.001
Immunomodulating drugs	3.25 (0.65, 16.37)	0.124
Musculoskeletal drugs	2.08 (1.32, 3.26)	NA
Analgesics	3.60 (2.25, 5.76)	<0.001
Psychotropic drugs	2.71 (0.85, 8.71)	0.07
Anti–depressants	0.94 (0.48, 1.82)	0.493
Anti–epileptics	2.07 (1.33, 3.23)	<0.001
Anxiolytics/Hypnotics	1.37 (0.83, 2.25)	0.136
Psycholeptics	0.90 (0.53, 1.54)	0.4
Psychostimulants	0.77 (0.38, 1.56)	0.293
Other NS drugs	1.08 (0.68, 1.73)	0.412
Respiratory and sensory drugs	3.07 (1.82, 5.18)	<0.001
Other	1.06 (0.15, 7.60)	0.5



Note. CI: confidence interval
NSAID: nonsteroidal anti-inflammatory drugs
Other NS drugs: other nervous system drugs

Supplementary Figure S4.

Medication prescriptions in patients with severe vs les-severe anorexia nervosa (severity evaluated at 3 years post-diagnosis)

Medication	Severe AN (%)	Less-severe AN (%)	Odds Ratio (95% CI)	P-value
Alimentary tract	44.9	38.4	1.30 (1.17, 1.46)	< 0.001
Gastrointestinal	37.8	33.0	1.23 (1.10, 1.38)	< 0.001
Vitamins/Minerals	12.8	4.6	3.07 (2.54, 3.71)	< 0.001
Cardiovascular drugs	24.7	24.4	1.02 (0.90, 1.15)	0.411
Iron preparations	3.0	1.7	1.79 (1.27, 2.53)	< 0.001
Anti–infective drugs	91.5	94.5	0.62 (0.51, 0.76)	< 0.001
Contraceptives	71.2	77.6	0.72 (0.63, 0.81)	< 0.001
Hormonal preparation drugs	10.2	9.1	1.14 (0.95, 1.36)	0.094
Thyroid therapy	3.6	2.9	1.23 (0.91, 1.66)	0.105
Musculoskeletal drugs	38.2	43.0	0.82 (0.73, 0.91)	< 0.001
NSAID	37.2	42.3	0.81 (0.72, 0.90)	< 0.001
Bisphosphonates	1.2	0.6	1.94 (1.12, 3.36)	0.012
Immunomodulating drugs	1.3	2.0	0.66 (0.41, 1.04)	0.043
Analgesics	34.2	32.2	1.10 (0.98, 1.23)	0.063
Psychotropic drugs	74.7	60.0	1.97 (1.75, 2.23)	< 0.001
Anti–epileptics	15.4	10.5	1.56 (1.33, 1.82)	< 0.001
Psycholeptics	33.5	17.1	2.44 (2.16, 2.76)	< 0.001
Anxiolytics/Hypnotics	36.6	26.0	1.64 (1.46, 1.84)	< 0.001
Anti–depressants	62.0	44.2	2.06 (1.84, 2.31)	< 0.001
Psychostimulants	3.9	4.3	0.91 (0.69, 1.20)	0.278
Other NS drugs	11.1	7.1	1.64 (1.37, 1.97)	< 0.001
Respiratory and sensory drugs	57.7	62.0	0.84 (0.75, 0.94)	< 0.001
Other	0.6	0.6	1.02 (0.50, 2.07)	0.5



Note. AN: anorexia nervosa
CI: confidence interval
NSAID: nonsteroidal anti-inflammatory drugs
Other NS drugs: other nervous system drugs

Supplementary Figure S5.

Medication prescriptions in patients with severe vs less-severe anorexia nervosa (severity evaluated at 7 years post-diagnosis)

Medication	Severe AN (%)	Less-severe AN (%)	Odds Ratio (95% CI)	P-value
Alimentary tract	37.4	26.5	1.65 (1.47, 1.85)	< 0.001
Gastrointestinal	28.5	21.8	1.43 (1.27, 1.62)	< 0.001
Vitamins/Minerals	11.2	2.6	4.67 (3.74, 5.82)	< 0.001
Cardiovascular drugs	21.2	18.2	1.21 (1.06, 1.38)	0.003
Iron preparations	1.6	0.8	1.87 (1.17, 2.98)	0.006
Anti–infective drugs	81.7	84.7	0.81 (0.70, 0.93)	0.002
Contraceptives	59.3	67.8	0.69 (0.62, 0.77)	< 0.001
Hormonal preparation drugs	8.2	7.0	1.19 (0.98, 1.45)	0.048
Thyroid therapy	3.3	2.6	1.26 (0.92, 1.71)	0.087
Musculoskeletal drugs	29.7	30.5	0.96 (0.86, 1.08)	0.276
NSAID	28.4	29.5	0.95 (0.84, 1.07)	0.187
Bisphosphonates	1.3	0.3	4.06 (2.23, 7.42)	< 0.001
Immunomodulating drugs	1.1	1.4	0.78 (0.47, 1.29)	0.195
Analgesics	28.4	25.1	1.18 (1.05, 1.33)	0.003
Psychotropic drugs	61.2	39.2	2.44 (2.19, 2.73)	< 0.001
Anti–epileptics	13.4	7.7	1.86 (1.57, 2.20)	< 0.001
Psycholeptics	26.7	11.2	2.88 (2.52, 3.29)	< 0.001
Anxiolytics/Hypnotics	29.4	17.1	2.03 (1.79, 2.29)	< 0.001
Anti–depressants	50.8	29.9	2.42 (2.17, 2.70)	< 0.001
Psychostimulants	3.9	3.0	1.32 (0.99, 1.76)	0.033
Other NS drugs	8.6	4.7	1.92 (1.56, 2.36)	< 0.001
Respiratory and sensory drugs	41.9	44.0	0.92 (0.83, 1.02)	0.068
Other	0.2	0.4	0.52 (0.18, 1.48)	0.15



Note. AN: anorexia nervosa
CI: confidence interval
NSAID: nonsteroidal anti-inflammatory drugs
Other NS drugs: other nervous system drugs

Supplementary Figure S6.

Comorbidity profiles of patients with severe anorexia nervosa
(severity evaluated at 3 years post-diagnosis, derived from latent class analysis)

Cluster 1: Severe AN patients without any comorbidities
N = 179, AN-RSI = 1.13 (1.15)[1]

Cluster 2: Severe AN patients with low burden of comorbidities
N = 571, AN-RSI = 1.16 (1.25)[1]



Cluster 3: Severe AN patients with medium burden of personality, mood, and anxiety disorders
N = 493, AN-RSI = 1.29 (1.07)[1]



Cluster 4: Severe AN patients with high burden of personality disorders, and self-harm conditions
N = 298, AN-RSI = 1.64 (0.95)[1]



Cluster 5: Severe AN patients with high burden comorbidities
N = 77, AN-RSI = 1.54 (1.27)[1]



Note. AN-RSI: Anorexia Nervosa Register-based Severity Index
[1]Mean(standard deviation);
Comorbidities with less than five cases were set to zero.

Supplementary Figure S7.

Comorbidity profiles of patients with severe anorexia nervosa
(severity evaluated at 7 years post-diagnosis, derived from latent class analysis)

Cluster 1: Severe AN patients without any comorbidities
N = 179, AN-RSI = 1.13 (1.15)[1]

Cluster 2: Severe AN patients with low burden of comorbidities
N = 456, AN-RSI = 1.21 (1.45)[1]



Cluster 3: Severe AN patients with medium burden of personality, mood, and anxiety disorders
N = 726, AN-RSI = 1.31 (1.39)[1]



Cluster 4: Severe AN patients with high burden of personality disorders, and self-harm conditions
N = 257, AN-RSI = 1.50 (1.34)[1]



Cluster 5: Severe AN patients with high burden comorbidities
N = 101, AN-RSI = 1.86 (1.64)[1]



Note. AN-RSI: Anorexia Nervosa Register-based Severity Index
[1]Mean(standard deviation);
Comorbidities with less than five cases were set to zero.